Research On Amrubicin Monotherapy To Treat Advanced Non-Small Cell Lung Cancer

Introduction, and Materials and Methods: There is currently no clear evidence on what treatments should constitute tertiary and subsequent treatments for advanced non-small cell lung cancer (NSCLC). Amrubicin monotherapy has recently been studied as a treatment for NSCLC and may represent a potential regimen for tertiary and subsequent treatments. This report summarizes 7 cases in which amrubicin monotherapy was used to treat advanced NSCLC.Results and Conclusion: In cases where "neutropenia" was noted, corresponding to grade 3 to 4 hematological toxicity, the patient's neutrophil count recovered with the administration of G-CSF, and amrubicin monotherapy was safely continued. This study will be continued in the future on a larger scale and in greater detail.